asthma
Conditions
Interventions
Group A:Utilin 1.72 ug*2+Saline 3ml, inhalation, once a day, 5 days/a course of treament.6days, one month, 3 months, 6 months, 1 year after treament review the indicator respectively, and carry one in
Group B:Seretide 50/100ug, do falling-rising ladder adjustment according GINA standard during the observation period. 6 days, one month, 3 months, 6 months, 1 year after treament review the indicator
Sponsors
Department of Public Health of Guangxi Zhuang Autonomous Region
Eligibility
Sex/Gender
All
Age
14 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. 14-17 years old outpatients had signed the informed consent and can follow up easily, non sexy limitation; 2. Patients diagnosed with bronchial asthma, bronchial provocation test postive, inhaled methacoline bronchial provocation test postive, (PD20-FEV1)=15%and FEV1 increase>=200ml; 3. Comply with 2008 GINA recommendations chronic light moderated standard; 4. not participated in other clinical research in last 3 months; 5. Chest X-ray: no obvious abnormality.
Exclusion criteria
Exclusion criteria: 1. Patients who be known or suspected severe allergy to any drug or lactose; 2. Women in prenancy, breathfeeding period or got prenancy during the research; 3. Patients who use Glucocorticoid, Ketotifen, Montelukast etc anti-inflammatory and anti-allergy drug within one month; 4. Smoking >=10 packs/year (1pack/year=one pack per day or 20x1year or the equivalent amount); 5. Patients who are taking ACEI /Beta blockers drugs. 6. Who got significant pulmonary infection and required antibiotic therapy; 7. Patients who be knowned got any severe disease or abnormality (like: cardiovascauar pulmonary disease except asthma, liver kidney disease and Neuro-endocrine disease. etc), participated the research may post a risk to them or affect the results; 8. Mental state and capacity cant assert the observation; 9. Someone who got any respiratory infections and affected the asthma within one month; 10. Someone who participate in another research within one month or during this reseach period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the number of gammadelta T cells and it's subsets(vgamma1+ cells, vgamma4+ cells);PEF;FEV1;PD20-FEV1;the amount and proportion of gammadelta T cells subsets(vgamma1+ cells, vgamma4+ cells) unique genet;the gene expression of IL-4, IL-5, IFN-gama; | — |
Secondary
| Measure | Time frame |
|---|---|
| AM PEF;PM PEF;ACT score; | — |
Countries
China
Contacts
Public ContactChaoqian Li
Outcome results
None listed